October 12, 2007 - Angiotech Pharmaceuticals Inc. said Oct. 11 it received CE Mark approval to begin marketing the Quill Self-Retaining System (SRS) MONODERM sutures in Europe.
This CE Mark approval follows Angiotech’s August clearance from the FDA to begin marketing the Quill SRS MONODERM product line in the United States.
Quill SRS MONODERM sutures, which are made from a rapidly resorbing polymer, are intended primarily for superficial wound closure applications and indicated for soft tissue approximation where use of an absorbable suture is appropriate. It is anticipated the sutures will be available in various lengths and needle configurations using three different diameters (USP sizes 0, 2-0 and 3-0).
Angiotech will exhibit the Quill SRS product line at the annual meeting of the American Society of Plastic Surgeons (ASPS Oct. 26-31 in Baltimore).
For more information: www.angiotech.com